ERT Announces Appointment of New President and CEO
Posted: 4 May 2011 | | No comments yet
ERT, has appointed Jeffrey S. Litwin, as its new President and Chief Executive Officer and as a member of the board…
Jeff Litwin, New CEO for ERT
ERT, a global technology-driven provider of clinical services and customizable medial devices to biopharmaceutical and healthcare organizations, announced today that its Board of Directors has appointed Jeffrey S. Litwin, M.D. its new President and Chief Executive Officer and as a member of the board.
Dr. Joel Morganroth, who had served as interim President and Chief Executive Officer, commented that “after a thorough national search by Heidrick and Struggles, our Board selected Dr. Litwin, an internal candidate, as the most qualified person to lead ERT. Jeff brings to ERT knowledge of the Clinical Research domain, that is our core business, and also experience in the adjacent markets of Phase IV safety surveillance and healthcare in which ERT’s assets will be employed. All of our employees look forward to continuing to work with Jeff to enhance ERT’s operational successes and strategy.”
Dr. Litwin joined ERT in 2000 as Senior Vice President and Chief Medical Officer and was subsequently promoted in December 2005 to Executive Vice President and Chief Medical Officer. Dr. Litwin oversaw ERT’s global cardiac safety operations for seven years and was instrumental in implementing EXPERT, ERT’s digital operating system. During this time period, ERT experienced tremendous growth with revenues increasing more than three-fold. For the last four years, he has been responsible for leading ERT’s consulting business, assisting over 150 companies with the design and evaluation of cardiac safety testing programs. Throughout his career at ERT, Dr. Litwin has also been directly involved in supporting ERT’s sales efforts.
In addition to his responsibilities at ERT, Dr. Litwin serves on the DIA Annual Meeting planning committee, the Applied Clinical Trials Editorial Board, and the Board of Directors of the Metrics Champion Consortium. Dr.
Litwin is a board-certified cardiologist and left his cardiology practice to serve as Director, Medical Affairs, Wyeth-Ayerst Laboratories from 1988 to 1990 where he had responsibility for medical services, Phase IV research, and pharmacovigilance for all marketed cardiac safety products. From 1990 to 1993, Dr. Litwin served as Deputy Medical Director of Nutri/System Inc., and from 1993 until joining ERT, Dr. Litwin served as Executive Vice President and Chief Operating Officer of Executive Health Group, the nation’s leading provider of executive physical examinations. In that role, he built a worldwide network of over 1000 physician offices to provide pre-employment physicals and high quality physical examinations to corporate executives.
Dr. Litwin commented, “It has been a great pleasure working with the employees, management team and Board at ERT for the past 11 years. This experience should allow for a seamless transition from Dr. Morganroth’s service as our interim President and Chief Executive Officer. The acquisition of Research Services has transformed ERT by expanding the services and products we offer, and I look forward to leading the company in the implementation of our strategic plan both within the clinical research market as well as adjacent markets. I also thank Dr. Morganroth for his dedicated service as our interim President and Chief Executive Officer over these past few months.”
The Board also elected Elam M. Hitchner, III to succeed Dr. Morganroth as Chairman. Mr. Hitchner has served since April 2010 as the lead independent director of the Board. Echoing Dr. Litwin’s comments, Mr. Hitchner stated, “We thank Dr. Morganroth not only for his service as our interim President and Chief Executive Officer but also for having served as our Chairman since 1999. Our Board believed that, with the appointment of Dr. Litwin as our President and Chief Executive Officer, this was an opportunity to enhance our corporate governance by appointing a non-executive Chairman.”
Dr. Morganroth commented, “I am excited to be able to focus on my duties as Chief Scientific Officer as we continue to implement our strategic plan of growing our core business while expanding beyond that business into other areas. I will continue to have input in the overall direction of our business in my role as a member of the Board, and I look forward to the continued growth of ERT.”